Immune Cell Changes Around Surgery and Colorectal Cancer Outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, non-interventional observational study conducted at Beijing Friendship Hospital to explore real-world immune indicators around the perioperative period in colorectal cancer patients. The study analyzes whether perioperative immune changes predict overall survival and progression-free survival. Data will come from patients treated under routine clinical pathways, without adding burdens to patients or resources. The aim is to identify the best indicators to forecast prognosis in patients after surgery, including those with metastases who are still operable.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18-85 years old, regardless of gender;
* Patients with newly diagnosed CRC who are planned to undergo surgery (including patients with metastases but still feasible for surgery);
* Patients who have not been diagnosed for the first time and have not received surgical treatment and now planned to undergo surgery(e.g., patients after neoadjuvant radiotherapy and chemotherapy for middle and low rectal cancer).

Exclusion Criteria:

* Patients who refused to sign informed consent;
* Patients complicated with other tumors;
* Pregnant or lactating women;
* People with a history of psychotropic drug abuse and unable to quit or those with mental disorders;
* Postoperative histopathological examinations for patients with non-CRC type;
* Patients who could not be followed up.

Where it's running

• Beijing Frendship Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Zhongtao Zhang, doctor
• Email: zhangzht@ccmu.edu.cn
• Phone: 13801060364

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Liver transplantation for colorectal cancer with liver metastases

  This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07884110

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.